Nical trials conducted in OS patients with recurrence, chemoresistance, or lung metastasis discovered moderately clinical responses in subgroup of patients.28,29 Ideally, experimental investigation of expression of tyrosine kinases is the prerequisite for choosing individuals who will acquire a true advantage from this targeted remedy. One of these trials examined the expression and mutation profi